Ipamorelin
Made it into real human trials, then was dropped. Selective, short-acting, and genuinely studied — just not approved.
Not approved anywhere
| What it is | A synthetic pentapeptide that acts on the ghrelin receptor to trigger a pulse of growth hormone. |
|---|---|
| How it is thought to work | Binds the growth hormone secretagogue receptor in the pituitary. Unlike older compounds in its class it has little effect on cortisol or prolactin, which is why it drew interest. |
| What the evidence actually shows | Developed by Novo Nordisk and taken into human trials for post-operative ileus. It did not meet its endpoints and development stopped. So there is real human safety data, but no evidence of benefit for the uses it is discussed for now. |
| Regulatory status | Not approved anywhere. Development discontinued by its originator. |
| Dosing | No approved dose. Doses used in the discontinued ileus trials were studied for a different purpose on a short hospital timeline and do not transfer to ongoing use. |
| In the catalog as |
Risks and cautions
- Raising growth hormone affects blood sugar and can cause fluid retention and joint pain.
- Anyone with an active cancer, or a history of one, should not be raising GH or IGF-1 without an oncologist involved.
- Prohibited in sport by WADA.
Before you act on any of this
This page describes what is known and what is not. It is not a recommendation to use anything, and it is not a protocol. Compounds listed as research chemicals are not approved medicines and are not sold for human use. Talk to a doctor who knows your history.